Home FOR AUTHORS Neoplasma 2016 Neoplasma Vol.63, No.1, p.37-43,2016

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.63, No.1, p.37-43,2016

Title: In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy
Author: C. Y. ZHANG, L. J. ZHANG, J. W. LI, J. H. LI, Z. M. WU, L. X. ZHANG, N. CHEN, Y. J. YAN, Z. L. CHEN

Abstract: In presented paper, a new chlorin derivative 5,10,15,20-tetrakis[(5-N-morpholino)pentyl] chlorin (TMC) was investigated as a photosensitizer in photodynamic therapy (PDT). Cellular uptake, cytotoxicity, intracellular location, biodistribution and antitumor effects were studied using human esophageal cancer cells (Eca-109) and human cervical cancer cells (Hela) in vitro and an esophageal cancer model in BALB/c nude mice. Cellular uptake and biodistribution of TMC were measured by fluorescence spectrophotometer. Cytotoxicity of TMC against Eca-109 and Hela cells was determined by MTT assay. The intracellular location of TMC was detected with a confocal microscopy. It was showed that TMC could rapidly accumulate in tumor cells and localize in cytoplasm. TMC was found to be low-toxic in dark but extensively photosensitive in vitro. A fast clearance rate of TMC was observed in Eca-109-bearing mice. In particular, TMC could significantly inhibit the tumor growth and exhibit a notable antitumor efficacy for PDT in vivo.

Keywords: photodynamic therapy, photosensitizer, tumor, chlorin
Published online: 16-Jan-2016
Year: 2016, Volume: 63, Issue: 1 Page From: 37, Page To: 43
doi:10.4149/neo_2016_005


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.